David Horst
YOU?
Author Swipe
View article: Differential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes
Differential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes Open
Urinary bladder cancer is the tenth most common malignancy worldwide and represents a major global health burden [...]
View article: AML maturation stages associate with disease-permissive and immunosuppressive effects in newly diagnosed AML patients: An analysis at the single-cell level
AML maturation stages associate with disease-permissive and immunosuppressive effects in newly diagnosed AML patients: An analysis at the single-cell level Open
Introduction: The clinical outcome of acute myeloid leukemia (AML) is determined by therapy resistance and relapse. AML-induced immunosuppression has emerged as one of many cofactors and seems to be caused by distinct mechanisms, e.g. immu…
View article: Supplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Overview of antibodies used for staining and cutoffs in TMA analysis.
View article: Supplementary Table S10 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S10 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Multivariate Cox regression analyses with regard to prognostic impact of Immunoactivation-Score in terms of progression-free survival and overall survival since start of maintenance treatment.
View article: Supplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Risk analysis of Overall Response Rates in the epithelial tumor of tumor center and invasive margin in the Maintenance set by treatment arm.
View article: Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Analysis of progression-free survival within the maintenance therapy set by high/low immune expression and treatment arm. Mean Values of Epithelial Tumor and Stromal Cells.
View article: Supplementary Figure S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Forest plot of univariate Cox Regression Analysis of progression-free survival and overall survival within epithelial tumor expression in the invasive margin and overall stromal expression of the induction therapy set.
View article: Supplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Odds Ratios and 95% Confidence Intervals regarding ORR of immunoexpression in the epithelial tumor in the tumor center and the invasive margin after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
View article: Supplementary Table S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Representativeness of study participants
View article: Data from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Data from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Purpose:Tumor immune cell infiltration patterns in the tumor microenvironment serve as prognostic biomarkers in metastatic colorectal cancer. This study analyzed the spatially resolved tumor immune microenvironment for prognostic and predi…
View article: Supplementary Table S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Odds Ratios and 95% Confidence Intervals regarding ORR of immunoexpression in the epithelial tumor in the tumor center and the invasive margin after exclusion of cases with BRAF V600E and MSI – Induction Set
View article: Supplementary Table S9 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S9 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Interaction of positive/negative Immunoscore and Immunoactivation Score with maintenance treatment in terms of PFS and OS in the PanaMa trial.
View article: Supplementary Table S7 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S7 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Hazard Ratios and 95% Confidence Intervals regarding OS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Induction Set.
View article: Supplementary Table S13 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S13 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Hazard Ratios and 95% Confidence Intervals regarding OS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
View article: Supplementary Table S12 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S12 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Hazard Ratios and 95% Confidence Intervals regarding PFS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
View article: P08.02.B HIGH-GRADE IMMUNE-RELATED ADVERSE EVENTS AND PATIENT OUTCOMES FOLLOWING POST-OPERATIVE CHECKPOINT INHIBITION IN RESECTED BRAIN METASTASES: A RETROSPECTIVE COHORT STUDY
P08.02.B HIGH-GRADE IMMUNE-RELATED ADVERSE EVENTS AND PATIENT OUTCOMES FOLLOWING POST-OPERATIVE CHECKPOINT INHIBITION IN RESECTED BRAIN METASTASES: A RETROSPECTIVE COHORT STUDY Open
BACKGROUND Immune checkpoint inhibitors (ICIs) are increasingly used in patients with brain metastases, yet their postoperative safety and efficacy remain unclear. This study evaluates survival outcomes and high-grade immune-related advers…
View article: Supplementary Table S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Confidence intervals, medians and P of IHC measurements. Paired-sampled t-test of stromal and epithelial immune infiltration in each tumor region.
View article: Supplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Analysis of overall survival within the maintenance therapy set by high/low immune expression, tumor region and treatment arm.
View article: Supplementary Table S8 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S8 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Patient Characteristics of induction and maintenance PanaMa populations and positive/negative Immunoactivation Score subpopulations.
View article: Supplementary Figure S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Figure S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Risk analysis of Overall Response Rates in the Induction set.
View article: Supplementary Table S6 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S6 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
P, Hazard Ratios and 95% Confidence Intervals regarding PFS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Induction Set.
View article: Supplementary Table S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Supplementary Table S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial Open
Patient Characteristics of PanaMa population and TMA-subpopulation.
View article: Figure S10 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S10 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S10 displays differences in celltypes between the cohorts A) for LTS and B) for STS based on CIBERSORT results.
View article: Table S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
The Table S1 shows the Patient ID, Cancer Stage and the Residual _Tumor status of the TCGA paired cohort grouped by the Survival Group.
View article: Table S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S4 displays the characteristics and subtypes of the Charité cohort.
View article: Table S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S5 depicts the BRCA1/2, KRAS Status and HRD-Scores in LTS and STS in the Charité Cohort.
View article: Figure S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S1 shows a REMARK Diagram of the Charité Cohort construction.
View article: Figure S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S2 displays the Proportions of Molecular subtypes of LTS and STS in the Charité cohort and n the TCGA cohort.
View article: Data from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Data from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Purpose:The late-stage diagnosis and the aggressiveness of high-grade serous tubo-ovarian carcinoma (HGSC) often result in poor survival outcomes, yet some patients exhibit an exceptionally long survival rate. This study aimed to identify …